# Guilin Sanjin Group

Guilin Sanjin Group is a Corporate Investor based in Guilin, China.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Guilin, China
- **Region:** Asia
- **Address:** No. 9 Renmin South Road, Lingui District, Guilin, Guangxi, China
- **Founded:** 1967
- **Assets under management:** Undisclosed
- **Website:** guilinsanjin.com

## Regulatory record

- **Reports private funds:** No

## About

Guilin Sanjin Group is a corporate investor based in Guilin, China. It manages approximately $686.87 million in assets across two funds, primarily focusing on Asia.

## Sectors

- Healthcare Services
- Real Estate

## Offices

- Shanghai, China

## People

- Zou Xun — Chairman and President
- Zou Hong — Vice Chairman
- Zou Zhun — Director and Vice President

## Questions

### Who controls Guilin Sanjin Group's investment decisions?

The late founder Zou Jieming consolidated ownership among his wife Weng Shizhen and three sons. Zou Xun, the eldest son, serves as Chairman and President of both the holding group and the listed pharmaceutical entity. Vice Chairman Zou Hong and Vice President Zou Zhun — who runs the Shanghai biotech operations — round out the family investment committee. There is no disclosed external advisory board or institutional investment committee.

### What is the relationship between Guilin Sanjin Group and the Shenzhen-listed entity?

Guilin Sanjin Group is the controlling shareholder of Guilin Sanjin Pharmaceutical Co., Ltd. (SZ: 002275), which listed on the Shenzhen Stock Exchange in 2009. The listed entity contains the branded Chinese patent medicine business — including the Sanjin Pian and Watermelon Frost product lines — while the unlisted holding company also holds the group's real estate assets and Shanghai biotech subsidiaries.

### What happened to the founder, and how was succession handled?

Zou Jieming died in 2021. He had already installed his three sons in senior operating roles — Zou Xun as the listed company's Chairman, Zou Hong as group Vice Chairman, and Zou Zhun as Vice President over Shanghai biotech operations. The founder's widow, Weng Shizhen, retained a significant individual shareholding. No public boardroom dispute or equity restructuring followed the transition.

### What investment stages or areas does Guilin Sanjin Group avoid?

The group does not invest in early-stage technology startups, Western pharmaceutical drug development outside traditional Chinese medicine frameworks, or any sector outside its core pharma-real estate dual mandate. There is also no record of cross-border direct investments, external minority co-investments alongside other family offices, or commitments to blind-pool private equity funds.

## Related profiles

- [Guilin Economic Construction Investment Group](https://altss.com/profile/guilin-economic-construction-investment-group)
- [Guirenniao](https://altss.com/profile/guirenniao)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/guilin-sanjin-group

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology